AU2016295650A1 - Method for treatment of traumatic brain injury targeting aggregated peptides - Google Patents

Method for treatment of traumatic brain injury targeting aggregated peptides Download PDF

Info

Publication number
AU2016295650A1
AU2016295650A1 AU2016295650A AU2016295650A AU2016295650A1 AU 2016295650 A1 AU2016295650 A1 AU 2016295650A1 AU 2016295650 A AU2016295650 A AU 2016295650A AU 2016295650 A AU2016295650 A AU 2016295650A AU 2016295650 A1 AU2016295650 A1 AU 2016295650A1
Authority
AU
Australia
Prior art keywords
brain injury
peptides
traumatic brain
agent
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016295650A
Other languages
English (en)
Inventor
Hans Basun
Lars Lannfelt
Erik Rollman WAARA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic Neuroscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Neuroscience AB filed Critical Bioarctic Neuroscience AB
Publication of AU2016295650A1 publication Critical patent/AU2016295650A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016295650A 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides Abandoned AU2016295650A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195183P 2015-07-21 2015-07-21
US62/195,183 2015-07-21
US201662288813P 2016-01-29 2016-01-29
US62/288,813 2016-01-29
PCT/IB2016/054318 WO2017013599A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Publications (1)

Publication Number Publication Date
AU2016295650A1 true AU2016295650A1 (en) 2018-01-25

Family

ID=56550266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016295650A Abandoned AU2016295650A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Country Status (7)

Country Link
US (1) US11327080B2 (cg-RX-API-DMAC10.html)
EP (1) EP3325506A1 (cg-RX-API-DMAC10.html)
JP (2) JP2018522891A (cg-RX-API-DMAC10.html)
CN (1) CN107849125A (cg-RX-API-DMAC10.html)
AU (1) AU2016295650A1 (cg-RX-API-DMAC10.html)
CA (1) CA2991856A1 (cg-RX-API-DMAC10.html)
WO (1) WO2017013599A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165271A2 (en) 2013-03-13 2014-10-09 Neotope Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
SG11201910066QA (en) 2017-05-02 2019-11-28 Prothena Biosciences Ltd Antibodies recognizing tau
TWI859197B (zh) 2019-03-03 2024-10-21 愛爾蘭商普羅帝納生物科學公司 識別ｔａｕ之抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
EP1827493A4 (en) * 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR TREATING TRAUMATIC BRAIN INJURY
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2470211B1 (en) 2009-08-28 2016-01-27 The Board of Regents of The University of Texas System Antibodies that bind tau oligomers
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
AU2011326564A1 (en) * 2010-11-10 2013-05-09 Genentech, Inc. Methods and compositions for neural disease immunotherapy
US20150118231A1 (en) * 2012-05-08 2015-04-30 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
EP2928494A4 (en) * 2012-12-07 2016-11-02 Biogen Internat Neuroscience Gmbh METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates
CN106661103B (zh) * 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体

Also Published As

Publication number Publication date
JP2022113682A (ja) 2022-08-04
EP3325506A1 (en) 2018-05-30
US11327080B2 (en) 2022-05-10
JP2018522891A (ja) 2018-08-16
CA2991856A1 (en) 2017-01-26
US20180209994A1 (en) 2018-07-26
WO2017013599A1 (en) 2017-01-26
CN107849125A (zh) 2018-03-27

Similar Documents

Publication Publication Date Title
Zhao et al. β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice
JP2022113682A (ja) 凝集ペプチドを標的とする外傷性脳損傷の治療方法
US9730979B2 (en) Methods for decreasing set in inhibiting protein phosphatase 2A (PP2A) and/or increasing the activity of cyclin-dependent kinase 5 (CDK5) by an APOE peptide
Li et al. Astrocyte-derived TNF-α-activated platelets promote cerebral ischemia/reperfusion injury by regulating the RIP1/RIP3/AKT signaling pathway
Cisbani et al. Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Kaur et al. Intracellular DAMPs in neurodegeneration and their role in clinical therapeutics
TWI873177B (zh) 治療性融合蛋白
HK1258529A1 (zh) 用於治疗神经退行性和神经炎性病症的方法和组合物
Tambaro et al. Blood–brain and blood–cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice
Panza et al. Passive tau-based immunotherapy for tauopathies
WO2022198073A1 (en) Compositions and methods for targeting inflammatory or arctivated cells and treating or ameliorating inflammatory conditions and pain
WO2021221784A2 (en) Circular bifunctional aptamers and trifunctional aptamers targeting tau
US10889625B2 (en) Peptide-based methods for treating neurological injury
WO2022214494A2 (en) A new non-aggregative splicing isoform of human tau is decreased in alzheimer's disease
EP4058470A2 (en) Novel peptide compositions and methods of treating neurological injury
CN106794222A (zh) 使用p75ecd和/或p75诊断或治疗神经障碍的方法
US9045525B2 (en) Amyloid β-protein-specific production-inhibiting polypeptide
EP3900736A1 (en) Composition comprising a dna-degrading enzyme for use in a method for the treatment of immunosuppression after acute tissue injury
TW202506139A (zh) 米韋爾西蘭（Ｍｉｖｅｌｓｉｒａｎ）組合物及其使用方法
Saxena et al. High-Mobility Group Box-1 and Its Potential Role in Perioperative Neurocognitive Disorders. Cells 2021, 10, 2582
WO2025184593A1 (en) Tau-targeting therapy for alzheimer's disease and other tauopathies
WO2023246847A1 (zh) B2M-GluN1封闭肽、其药物组合物及用途
Wang et al. Endothelial Genetic Deletion of CD147 Induces Changes in the Dual Function of the BBB and Is Implicated in Alzheimer's Disease
Oyesola et al. SLEEP DEPRIVATION AND COFFEE CONSUMPTION INDUCED CHANGES IN BMI, BLOOD PRESSURE AND BLOOD GLUCOSE IN MALE WISTAR ALBINO RATS
Sontheimer MINI-REVIEW A role for glutamate in growth and invasion of primary brain tumors

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application